Fate Therapeutics (FATE) EBITDA Margin (2012 - 2026)
Fate Therapeutics (FATE) reported EBITDA Margin of 2417.71% for Q1 2026, down 10353.0% on a YoY basis from N/an in Q1 2025, and down 2.12% quarter-over-quarter from 2367.49% in Q4 2025.
Fate Therapeutics (FATE) EBITDA Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics has reported EBITDA Margin for 14 years, with the latest figure at 2417.71% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 10353.0% year-over-year to 2417.71%; the trailing twelve-month figure through Mar 2026 stood at 2061.04% (down 74499.0% YoY), and the FY2025 full-year result was 2053.37%, down 68877.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 2417.71%, down from 2367.49% in the prior quarter.
- The five-year high for EBITDA Margin was 29.96% in Q1 2023, with the low at 5648.02% in Q2 2023.
- Historically, EBITDA Margin has averaged 1777.69% across 5 years, with a median of 1847.16% in 2025.
- Annual changes were most pronounced in 2023 — EBITDA Margin slumped 523486 bps — and 2024, when it soared 507721 bps.
- Fate Therapeutics' EBITDA Margin stood at 123.92% in 2022, then slumped by 2000 bps to 2601.91% in 2023, then dropped by 9 bps to 2834.41% in 2024, then rose by 16 bps to 2367.49% in 2025, then retreated by 2 bps to 2417.71% in 2026.
- The last three EBITDA Margin figures came in at 2417.71% (Q1 2026), 2367.49% (Q4 2025), and 1847.16% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -2,417.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,417.71% |
| Dec 31, 2025 | -2,367.49% |
| Sep 30, 2025 | -1,847.16% |
| Jun 30, 2025 | -1,793.34% |
| Mar 31, 2025 | -2,314.18% |
| Dec 31, 2024 | -2,834.41% |
| Sep 30, 2024 | -1,510.12% |
| Jun 30, 2024 | -570.81% |
| Mar 31, 2024 | -2,504.57% |
| Dec 31, 2023 | -2,601.91% |
| Sep 30, 2023 | -2,319.03% |
| Jun 30, 2023 | -5,648.02% |
| Mar 31, 2023 | -29.96% |
| Dec 31, 2022 | -123.92% |
| Sep 30, 2022 | -556.94% |
| Jun 30, 2022 | -413.15% |
| Mar 31, 2022 | -368.08% |
| Dec 31, 2021 | -406.06% |
| Sep 30, 2021 | -304.36% |
| Jun 30, 2021 | -409.77% |